Sales of Eli Lilly’s (LLY) blockbuster weight-loss drug Zepbound surged in the fourth quarter despite missing the company’s ...

People taking weight-loss drugs say they are losing their sight. Science is trying to figure out why - There’s no direct link between vision loss and taking the weight loss and diabetes drugs such as ...

When Jeanne began to seriously consider taking Zepbound, one of the new-generation weight-loss drugs, she had the briefest of ...

Eli Lilly investors and analysts said they want to hear details from the company on how exactly it plans to grow U.S. sales ...

In fact, Novo Nordisk recently reported positive results for one of its anti-obesity candidates that puts its current ...

Approximately 15.5 million Americans have been or currently are on injectable diabetes or weight-loss medications known as ...

An ad airing Super Bowl Sunday features “America’s deadliest epidemic,” obesity, and what can be done about it with the use of “affordable” compounded weight loss drugs.

Eli Lilly (NYSE: LLY) has underperformed broader equities. While that's not much of an issue in the grand scheme of things, ...

Tirzepatide, found in Mounjaro and Zepbound, mimics both GIP and GLP-1 hormones to activate insulin production. Semaglutide, ...

The use of blockbuster weight loss drugs has surged among young women, for whom the treatments can often be "liberating." ...

WVU Medicine is playing a lead role in a national clinical study of a minimally invasive surgical procedure for people who've ...